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ABSTRACT 
Background: Mycobacterium tuberculosis (Mtb) poses a major global health 
problem.   According to the World Health Organization, South Africa is a country with 
one of the highest reported incidence rates of this disease.  Key to overcoming this 
preventable and treatable disease lies in establishing a reliable and rapid diagnostic 
approach.   
Aims and Objectives: This study aims to investigate the validity of the 
mycobacterium polymerase chain reaction (PCR) assay applied to formalin-fixed, 
paraffin-embedded tissue in which the histology showed granulomatous 
inflammation with no demonstrable acid-fast bacilli.   
Methods: A retrospective, cross sectional and non-interventional study was 
conducted on 121 histopathology cases showing granulomatous inflammation with a 
negative Ziehl-Neelsen (ZN) stain. The mycobacterium PCR results obtained in 
these cases were compared against the results of mycobacterium culture obtained 
from a specimen derived from the same or related site as the biopsy.  
Results: The mean age of the study population was 35.3 years and the study cohort 
included 63 males and 58 females.  The sensitivity of nested mycobacterium PCR 
(detecting the 133 base pair product of the heat shock protein 65 kilo Dalton gene), 
was 64.1% and the specificity was 68.2%. The positive and negative predictive 
values were 49% and 80% respectively.  Twenty six of the 121 cases studied had a 
false positive result (21.5%).  
CONCLUSION: There are many factors that may influence the result of a PCR 
assay and the interpretation thereof.  Some of these factors include the inability of 
 v 
 
the test to distinguish between live and dead bacilli, the high risk of carry over 
contamination, and the paucibacillary nature of certain samples with an unequal 
distribution of the few bacilli that may be present.  Although the sensitivity and 
specificity of mycobacterium PCR on paucibacillary, formalin-fixed, paraffin 
embedded tissue is suboptimal, the interpretation of these results must be performed 
in conjunction with the overall clinical presentation of the patient.  
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CHAPTER  1 
 
1.0 Introduction 
Mycobacterium tuberculosis (Mtb) remains a major global health problem, despite 
rapid advancements in the medical field.1  Key to decreasing the morbidity and 
mortality rate of this disease lies in early detection by rapid and accurate diagnostic 
testing.  Unfortunately, patients that are clinically suspected of having the disease 
are often sputum smear negative.2 This is particularly true in the Human 
Immunodeficiency Virus (HIV) positive population.3  As such, tissue biopsies are 
frequently submitted for histopathological evaluation. 
Histologically, Mtb displays a pattern of necrotising granulomatous inflammation.  As 
other disease entities may present in this manner, a Ziehl-Neelsen (ZN) stain for 
acid-fast bacilli (AFB) is also performed, which if present, confirms mycobacterial 
infection.4  However, it is not uncommon that even in the presence of high clinical 
suspicion, the ZN stain is negative, with reported sensitivities of the ZN stain on 
histological samples ranging from 22% to 80%5. Culture, regarded as the gold 
standard test for detection of Mtb, is accurate but has the pitfall of taking 2-8 weeks 
to obtain a result6.  Furthermore, it is not uncommon that clinicians omit submitting a 
sample for culture at the time of biopsy. 
Another diagnostic test is the mycobacterium polymerase chain reaction (PCR), 
which may be performed on formalin-fixed, paraffin- embedded (FF-PE) tissue. This 
test is rapid, but its results are dependent on many variables, including primers used, 
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fixation time, concentration of DNA utilised, length of the PCR product and the PCR 
protocol itself7.  
This is a retrospective study with the aim of determining the validity of the 
mycobacterium PCR test utilised in our department. This will be achieved by 
comparing the PCR results with the culture results from the same or related biopsy 
site.  
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CHAPTER 2 
 
2.0 Aims and Objectives 
2.1 Aims 
The aim of this study is to investigate the validity of the mycobacterium polymerase 
chain reaction (PCR)  assay utilised in the department of Anatomical Pathology in 
evaluating histological specimens showing granulomatous inflammation without 
demonstrable acid-fast bacilli.  
 
2.2 Objectives 
The objectives of this study are as follows: 
 To compare the PCR result obtained from the formalin-fixed, paraffin 
embedded samples  with the culture result from the same or related site, (e.g. 
bone marrow trephine PCR with bone marrow aspirate culture). 
 Describe the age distribution of the study sample. 
 Determine the distribution of the biopsy sites. 
 Establish in how many cases a clinical suspicion of tuberculosis was raised, 
based on the clinical history provided. 
 Determine the number of patients on antituberculosis therapy at the time of 
biopsy. 
 Establish the number of patients in whom there was no clinical suspicion of 
tuberculosis, but the PCR results were positive and the culture results were 
positive. 
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 To determine in patients who were started on empirical antituberculosis 
treatment; how many cases yielded positive PCR and culture results 
respectively. 
 Establish the spectrum of mycobacterium species that were cultured and 
determine if the PCR assay yielded positive results when mycobacterium 
other than tuberculosis (MOTT) was grown by culture. 
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CHAPTER 3 
 
3.0 Literature Review 
3.1 Introduction 
Despite rapid advancements in the medical field, Mycobacterium tuberculosis (Mtb) 
still remains a major global health problem.  South Africa is regarded as a “high 
burden country” by the World Health Organization (WHO), with a reported incidence 
rate of 860 per 100 000 population in 2013.1  Key to curbing the scourge of this 
devastating, yet preventable and treatable disease, lies in establishing a quick 
diagnosis. Nucleic acid amplification techniques (NAATs) used for the detection of 
Mtb are rapid.  These include assays such as the GeneXpert (Xpert  MTB/RIF) which 
is an automated, real-time nucleic acid amplification assay for the concurrent 
detection of tuberculosis and rifampicin resistance.8,9  Line probe assays are able to 
detect the presence of M. tuberculosis complex as well as genetic mutations 
associated with isoniazid and rifampicin resistance.8,10,  These tests are rapid and 
accurate, but are primarily endorsed by the WHO for use on sputum and other fluid 
samples as well as fine needle aspirate samples.11  However, the use of these novel 
tests on histological samples is not yet widely applied.  Other PCR based 
methodologies have been proven useful on histological specimens, but the reliability 
of PCR is dependent on a number of parameters.   
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3.2 Epidemiology 
3.2.1 Statistics 
Tuberculosis (TB) was declared a global public health emergency by the World 
Health Organization (WHO) in 1993.  Today, more than 20 years later, this disease 
remains a worldwide health challenge.1 
The statistics are alarming.  In 2013, an estimated 9 million people developed 
tuberculosis and 1.5 million people died from the disease.1  Thirteen percent of the 
estimated 9 million people who developed TB in 2013, were HIV positive.  The 
South-East Asian and Western Pacific regions collectively accounted for 56% of the 
worlds’ TB cases in 2013.1  However, the African region had approximately one 
quarter of the world’s cases and the highest rates of cases and deaths relative to the 
population size.  South Africa, regarded as a high burden country by the World 
Health Organisation, falls within the top six countries worldwide with the highest 
incidence rates, with a reported rate of 860 per 100 000 population in 2013. 1  These 
figures highlight the difficulty in controlling this disease.  
 
3.2.2 Burden of Disease 
Tuberculosis places a major burden on the socioeconomic productiveness and 
viability of a country.  This is especially true in high prevalence countries, such as 
South Africa, where most TB patients are in their twenties to forties, and hence are 
the most economically productive generation.12 
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3.3 Controlling the disease 
The World Health Organization’s “Global Plan to Stop TB” strategy has a vision of a 
TB free world.  To accomplish this vision, goals have been set, amongst which are 
the millennium development goals. One of the millennium development goal targets 
is to reduce the TB incidence, prevalence and mortality rate by 50% in 2015, 
compared with their baseline levels in 1990.1  Whilst progress has been made 
toward reaching this target, in that the global prevalence has fallen by 41%  and the 
mortality rate has fallen by 45% between 1990 and 2013, the goal is far from being 
accomplished. 1 
 
One of the challenges towards achieving this goal is the emergence of multi-drug 
resistant tuberculosis (MDR TB).  This entity has a poor treatment outcome and is an 
important public health hazard and burden.12  Globally, approximately 3.5% of new 
TB cases and 20.5% of previously treated cases had MDR TB in 2013.1  In line with 
this issue is the emergence of extensively drug resistant (XDR) strains of 
Mycobacterium tuberculosis.  The detection and treatment of this disease is highly 
dependent on the results of high performance sensitivity tests.12    
 
A second challenge facing the health sector in curbing this disease is human 
immunodeficiency virus (HIV) and Mtb co-infection.  In 2013, an estimated 13% of 
the 9 million people globally who developed TB worldwide were HIV positive.1  In 
South Africa alone, a total of 328 896 cases of tuberculosis were notified in 2013.  Of 
these cases, 90% of patients were aware of their HIV status and 62% were HIV 
positive.  These figures highlight the burden of co-infection, particularly within the 
South African context. 1 
 Page | 8  
 
Priority actions are thus needed to accelerate progress towards the millennium 
development goals.  This includes early case detection and diagnosis, rapid testing 
and detection of MDR TB and HIV testing for TB patients.  This is to ensure 
appropriate treatment and infection control measures are instituted.  In May 2014, 
the World Health Assembly approved a ‘post- 2015 global TB strategy’.  This 
strategy aims for a target of a 95% reduction in TB mortality and a 90% reduction in 
TB incidence by 2035 worldwide (compared with 2015 levels).  Accurate and rapid 
TB diagnostics form a fundamental factor  in achieving this goal.1  
 
3.4 Diagnosis of Tuberculosis 
 
3.4.1 Conventional methods used for the diagnosis of Tuberculosis 
The most widely used, rapid and cost effective method for the diagnosis of 
pulmonary tuberculosis (PTB) is that of sputum smear microscopy with acid-fast 
bacilli staining, together with culture for M. tuberculosis.10,13  However, smear and 
mycobacterium culture can only be performed if a patient is productive of sputum,8 
and these traditional methods have a low sensitivity when sputum samples contain 
only a small number of organisms.2 
In order for acid-fast bacilli to be identified on the Ziehl-Neelsen (ZN) stain, 104 to 106 
bacilli per millilitre of tissue or fluid is required.13   An advancement in conventional 
tuberculosis microscopy is the development of fluorescent methods (e.g. auramine-
rhodamine staining) for the detection of bacilli.12  This method has increased the 
sensitivity over that of ordinary light microscopy.12 
Nevertheless, the gold standard test for the diagnosis of tuberculosis remains 
culture. 3  This method has a high specificity with a sensitivity of approximately one 
 Page | 9  
 
hundred fold more than that of smear microscopy.6  However, mycobacteria are 
notoriously slow growing, dividing once every 18-21 hours,14 and require 101 to 102 
bacilli per millilitre of sample for growth to occur.14,15  Although culture of M. 
Tuberculosis in Lowenstein-Jensen medium is a sensitive assay,10  it is a protracted 
process that includes isolation,  identification and drug susceptibility testing; thus can 
take at least 4 to 8 weeks for a result.6  In recent years, modern liquid media and 
growth detection systems have been developed, which have been shown to be more 
rapid and sensitive than the solid medium cultures. 12  The Mycobacteria Growth 
Indicator Tube (MGIT) is one of the novel culture methods that has an inbuilt 
fluorescent sensing system which detects even small amounts of bacterial growth 
based on oxygen concentration changes. 12  A meta-analysis comparing BACTEC 
MGIT960 and conventional solid media showed that the mean time to detection of 
bacterial growth (for all mycobacterial species) was 12.9 days as compared to 27.0 
days using the Lowenstein-Jensen solid medium. 16  Smear negative specimens took 
a mean time of 16.5 days as compared to 33.7 days using BACTEC MGIT960 and 
Lowenstein-Jensen medium respectively.16  Although the MGIT method of culture 
shows an improvement in the turn-around time for the culture result, there is still an 
inherent time limitation of all culture-based diagnostic assays.  This potentially has 
serious implications on patient management, as well as on the implementation of 
appropriate infection control measures.5  In resource poor settings, the selective use 
of mycobacterium culture is recommended, especially in cases with repeated 
negative smear results.15  Whilst culture is regarded as the gold standard diagnostic 
test for Mtb, the specificity of this test may also be diminished due to contamination 
of specimens in the laboratory. It is reported that despite the use of the best 
decontamination procedures, a false positive rate of 1 to 4% can be expected.15 
 Page | 10  
 
3.4.2  Role of cytology and histology in the diagnosis of Tuberculosis 
In the immunocompromised population, especially in those individuals infected with 
HIV, the diagnosis of tuberculosis is more challenging.  Factors contributing to this 
include an increase in the frequency of false negative sputa.3  This increase in 
sputum smear negativity is contradictory, as patients who are immunosuppressed 
tend to have higher bacterial loads.  The increase in false negative sputa is in part 
due to the decreased likelihood of bronchial damage and cavitation, thus decreasing 
the likelihood of bacilli being expelled in the sputum.3  Furthermore, the greater the 
degree of immune suppression, the greater the likelihood of extrapulmonary 
tuberculosis.  The frequency of extrapulmonary tuberculosis rises to greater than 
50% in those with severe immune deficiency.3  Therefore, in cases of suspected 
pulmonary TB (based on clinical features and chest X-Ray findings), with repeated 
negative sputum smear and culture results; and in cases with extrapulmonary 
involvement, the cytological as well as the histological evaluation of tissue samples 
play a key role in confirming the diagnosis.  
 
Tuberculous lymphadenitis is the commonest manifestation of extrapulmonary 
tuberculosis.17,18  It accounts for approximately 30-52% of cases of peripheral 
lymphadenopathy in countries with a high incidence of tuberculosis.17  In the setting 
of either peripheral lymphadenopathy or a palpable and accessible mass, fine needle 
aspiration biopsy (FNAB) has been shown to be the diagnostic procedure of 
choice.17,18  This procedure offers a feasible and safe option of specimen collection 
and can be easily performed in an out-patient setting.19   Fine needle aspiration 
biopsy has a diagnostic  yield that ranges from 42-83%.17,18  The procedure involves 
aspiration of a palpable mass utilising a syringe and needle and preparing at least 
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one smear for Papaniculaou staining and one air dried smear for Giemsa or Diff-
Quick staining and subsequent Ziehl-Neelsen staining.19  Residual material is 
subsequently  rinsed in mycobacterial culture media.19  Using the aforementioned 
method, a local study in HIV positive adults with suspected mycobacterial 
lymphadenitis showed a diagnostic yield of 80%.17  Whilst the use of cytology with 
confirmation of the presence of organisms using acid-fast stains has excellent 
diagnostic yields, speciation and drug sensitivity testing is only possible through 
mycobacterial culture or novel molecular techniques.17,19 
 
A major challenge in the diagnosis of extrapulmonary tuberculosis lies in the atypical 
clinical presentation of the disease, given that it often mimics other inflammatory and 
neoplastic conditions.9,20  A high degree of clinical suspicion is often required for an 
early diagnosis.  The problem is confounded in cases where the disease presents at 
sites that are not easily amenable to FNAB, such as the kidney, female genital tract 
or vertebral spine.9, 21, 22  In this clinical scenario, histopathological evaluation of 
tissue specimens play an important role in the diagnosis of tuberculosis. 
The key features that are suggestive of mycobacterial infection on histopathological 
examination include granulomatous inflammation, which may or may not show 
caseous necrosis, and Langhans-type giant cells.4  Although tuberculosis is the 
prototypical granulomatous disease, granulomatous inflammation can be found in a 
wide variety of clinical entities, amongst which include sarcoidosis, cat scratch 
disease, lymphogranuloma inguinale, leprosy, brucellosis, syphilis, mycotic 
infections, berylliosis and some autoimmune diseases. 4, 14, 20, 23 
By applying a Ziehl-Neelsen stain to the formalin-fixed, paraffin-embedded tissue, a 
diagnosis of tuberculosis can be confidently made if acid-fast bacilli (AFB) are 
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demonstrated.  Factors that influence the detection of AFB visualisation include the 
type of stain used (Ziehl-Neelsen stain , Kinyoun acid-fast stain, Fite stain, auramine-
rhodamine stain, or silver impregnation).24  The former three stains exploit the ability 
of the mycobacterium bacillus to retain their staining quality despite decolourisation 
with acids due to the large amount of lipid in their cell walls. 24   In formalin-fixed, 
paraffin embedded tissue, acid-fast stains have been shown to have a lower 
sensitivity, which may be attributable to the formalin and/or xylene treatment required 
for tissue processing.25  It is postulated that formalin and /or xylene may alter the 
property of the bacillus.25  Demonstration of the mycobacterial antigen by 
immunohistochemistry is also an option; however, this method has not been widely 
adopted. 24  Detection of mycobacteria is an often slow and tedious process.  Acid-
fast bacillus staining has a sensitivity ranging between 22-80%.5  A study 
investigating the sensitivity of the ZN stain in lymph node specimens previously 
diagnosed as tuberculous lymphadenopathy by conventional histopathology, showed 
that only 3% of cases were positive by ZN staining.26  Furthermore, another study 
showed that only 17 of the 53 (32%) of the histological samples showing 
granulomatous inflammation in patients who were clinically suspected as having TB, 
were AFB positive.25  It is therefore evident that in cases with a high clinical 
suspicion for tuberculosis that demonstrate granulomatous inflammation on 
histological sections, it is not uncommon for AFB not to be visualised.  Thus, 
mycobacterial infection cannot be conclusively diagnosed if the tissue was not 
submitted concurrently for mycobacterial culture.  The difficulty with extrapulmonary 
tissue samples is the paucibacillary nature of extrapulmonary disease.23  Due to the 
low yield of bacilli, extrapulmonary tuberculosis is associated with low sensitivity of 
acid-fast bacilli smear and culture evaluation.23  Nevertheless, it is extrapulmonary 
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TB, including tuberculous meningitis, pleural effusions and tuberculous osteoarthritis 
to name a few, that require a prompt, accurate and specific diagnosis.20  Therefore, 
developing a means for rapid, specific and sensitive identification of Mycobacterium 
tuberculosis is desirable.14 
 
3.4.3 Nucleic Acid Amplification Techniques 
The advent of molecular diagnostics has resulted in the development of rapid and 
sensitive assays which have revolutionised the diagnosis of tuberculosis.28  Nucleic 
acid amplification techniques (NAATs) are at the forefront of this technology.  There 
are currently two novel assays that use molecular detection methods that have been 
endorsed by the WHO for use on patient samples.  This includes the Xpert MTB/RIF 
assay and line probe assays. 8 
3.4.3.1 Xpert  MTB/RIF 
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, United States) is an automated, real time 
polymerase chain reaction (PCR) assay that can simultaneously detect 
Mycobacterium tuberculosis  DNA and rifampicin resistance in less than two hours.28  
This technology uses a closed cartridge system that contains preloaded liquid 
buffers and lyophilized reagent beads that are required to process the clinical 
sample.  The assay uses PCR based technology to amplify a 192 base pair (bp) 
segment of the bacterial ribose nucleic acid (RNA) polymerase rpoB gene.  Within 
this 192bp sequence, lies an 81bp region.  Greater than 95% of all rifampicin 
resistant strains of Mycobacterium tuberculosis contain mutations that are localised 
within this 81bp region.  Hence, it is possible to detect the presence of Mtb DNA and 
rifampicin resistance simultaneously by targeting a single gene target.8, 9  The assay 
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uses molecular beacon technology to detect amplicons using real-time PCR.  This 
technology utilises nucleic acid probes that recognise the presence or absence of 
the rifampicin susceptible (wild type) sequences within the rpoB gene of Mtb.  Five 
different coloured beacons are used, each spanning a different nucleic acid 
sequence within the rpoB gene.  When the beacon binds, it fluoresces, indicating 
that the rifampicin susceptible gene sequence is present.  Failure of fluorescence of 
a beacon is an indication that the sample is probably resistant to rifampicin.11 
In December 2010, the WHO endorsed the expansion of the Xpert MTB/RIF test.  
They recommended its use as the initial diagnostic test in adults and children 
presumed to have MDR TB or in HIV-associated TB.11  Since 2010, there has been a 
vast amount of research regarding the efficacy of the Xpert MTB/RIF test, including 
its use in the diagnosis of pulmonary, extrapulmonary and paediatric TB.  As a result, 
the WHO published a policy update, in which the contemporary research performed 
with regard to this assay was systematically reviewed.11 
The key findings from this policy update were as follows:11 
 When used as an initial diagnostic test, replacing conventional smear 
microscopy, Xpert MTB/RIF achieved a pooled sensitivity and specificity of 
88% and 99% respectively. 
 When used as an add-on test following a negative smear microscopy result, 
Xpert MTB/RIF yielded a pooled sensitivity and specificity of 68% and 99% 
respectively. 
 Xpert MTB/RIF on fresh or frozen tissue samples from any site excluding 
lymph nodes demonstrated varied sensitivities, ranging from 42% to 100%. 
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The pooled sensitivity and specificity was 81.2% and 98% respectively. 
(Twelve studies were included). 
 Performance of Xpert MTB/RIF on lymph node biopsy or aspirate samples, 
revealed a pooled sensitivity and specificity of 84.9% and 92.8% respectively. 
(Fourteen studies were included).11 
Given the above findings, the WHO recommendation for the use of Xpert MTB/RIF in 
the diagnosis of extrapulmonary TB and rifampicin resistance in adults and children 
is that “it may be used as a replacement test for usual practice (including 
conventional microscopy, culture or histopathology) for testing specific 
nonrespiratory specimens (lymph nodes and other tissues) from patients suspected 
of having extrapulmonary TB”. 11 
 
Three recent studies evaluating the Xpert MTB/RIF assay were conducted in South 
Africa, a country with one of the highest rates of TB and HIV prevalences.1   In the 
first study undertaken by Theron et al, 29 sputum samples from 496 patients with 
suspected TB (at two primary health care clinics in Cape Town), were analysed by 
Xpert MTB/RIF.  In this study, the sensitivity of the assay in smear positive, culture 
positive cases was 95% and the specificity was 94%. The sensitivity of smear 
negative cases was 55%.29   
The second study assessed the use of the Xpert MTB/RIF test in the diagnosis of 
spinal (extrapulmonary) TB in 71 patients.  In this study, the sensitivity and specificity 
of the assay was 95.6% and 96.2% respectively, as compared to the mycobacterium 
culture results.30  
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A recent, local study undertaken by Scott et al31 determined the diagnostic accuracy 
of Xpert MTB/RIF in extrapulmonary specimens.31  A total of 1175 specimens 
(including cerebrospinal fluid, fine needle aspirate samples, tissue samples, body 
cavity fluids, urine, stool and bone) were analysed with the Xpert MTB/RIF assay 
and compared to the culture results.  Only 2% of the study sample were tissue 
samples, for which an additional step of tissue homogenisation was required.  The 
Xpert MTB/RIF assay showed good performance in pus (sensitivity of 91%) and 
aspirate samples (sensitivity of 80%).  Although the sample size for the tissue 
specimens was too small to attain statistically significant results, the study showed 
that the Xpert MTB/RIF assay detected two more positive results as compared to 
culture.  Importantly, this study also illustrated that the Xpert MTB/RIF assay is less 
affected by contamination from bacteria as compared to culture.  Thus, its use in the 
diagnosis of extrapulmonary TB could reduce labour in the laboratory and 
subsequently diminish diagnostic delay.31 
However, to the investigator’s knowledge, the diagnostic use of Xpert MTB/RIF on 
FF-PE tissue has not been sufficiently evaluated.  Furthermore, the use of this assay 
on tissue samples is not part of the South African National Department of Health’s 
Xpert  algorithm.32  Thus, it is clear that although the Xpert MTB/RIF offers a rapid 
and sensitive method of diagnosing tuberculosis, with an additional advantage of 
detecting rifampicin resistance, other methods are required for the diagnosis of 
smear negative pulmonary TB and extrapulmonary TB on FF-PE tissue samples.  
3.4.3.2 Line probe assays 
Line probe assays were endorsed for use by the WHO in 2008 for the detection of 
Mtb and drug resistance from smear positive individuals who were at risk for MDR 
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TB.8  This technique is based on the principle of reverse hybridisation, in which 
mycobacterial RNA is amplified by PCR.10  Specific oligonucleotides  are immobilised 
at known locations on a membrane strip with a biotin labelled PCR product and the 
hybrids formed are detected colourimetrically.8  The commercially available 
MDRTBplus line probe assay (Hain Lifesciences, Germany) allows direct detection 
of M. tuberculosis, isoniazid and  rifampicin resistance from smear positive 
pulmonary specimens.8  This assay has not been endorsed for used on formalin 
fixed tissue specimens. 
 
 
3.4.3.3 Nested Polymerase Chain reaction (PCR) in formalin-fixed,   
           paraffin- embedded tissue 
Amplification of Mycobacterium tuberculosis DNA (deoxyribose nucleic acid) in 
formalin-fixed, paraffin-embedded (FF-PE) tissue samples is useful in patients with 
pulmonary and extrapulmonary TB, where the diagnosis depends on examination of 
tissue samples.2  PCR is of value when there is high clinical suspicion for 
tuberculosis, but clinical samples have not been submitted for culture.7  PCR 
performed on FF-PE tissue is of benefit under these circumstances, as this 
technique can detect the presence of mycobacterium DNA  in tissue that has been 
preserved in formalin or other fixatives that preclude the possibility of culture.2   The 
nested technique of PCR consists of two consecutive rounds of PCR.  The second 
round amplifies a DNA sequence within the first amplification product.33  This 
amplification assay can produce a result within two to three days, whereas culture 
may require between two to six weeks.7  The test can detect a limit of 1-10 bacilli in 
various clinical samples.14  In a study by Rish et al, as few as 9 organisms could be 
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detected by nested PCR in a 5 micrometer (µm) section of tissue.34  Factors that may 
affect the result of this assay have been extensively researched;  including the type 
of fixatives used, the DNA extraction procedure, the length of the PCR target, the 
concentration of the target DNA amplified and the PCR target itself.7 
A good target sequence for the PCR assay is one that will generate a species 
specific amplicon with a high degree of sensitivity and specificity.10  The target 
sequence for analysis should have the following features: 
1. A common sequence for all members of the mycobacterium genus, which 
may function as the primer binding site. 10 
2. Variability within the amplified region between the two primer binding sites 
which allows for differentiation between species.10   Thus, a vital aspect of 
this assay is the choice of a superior target sequence that will generate a 
species specific amplicon.10 
   
Targets for DNA amplification include the insertion sequence 6110 (IS6110), 65 kilo 
Dalton (kDa) heat shock protein (hsp65), MPB64 protein, 38KDa protein and 
ribosomal DNA.14   
Two commonly used targets in clinical practice are IS6110 and hsp65. 
IS6110 is usually present in multiple copies within the genome of all members of 
Mycobacterium tuberculosis complex.7  Species within the Mtb complex include M. 
tuberculosis (Mtb), M. bovis, M. bovis BCG, M. africanum, and M. microti.  The 
IS6110 sequence has been shown to have as many as 24 copies in Mtb, but only a 
few copies in M. bovis and only one copy in M. bovis BCG.14  The target sequence 
will not amplify in mycobacteria other than tuberculosis (MOTT), namely M. avium, 
 Page | 19  
 
M. intracellulare complex and M. Kansasii.5    Hence, the IS6110 target sequence is 
specific for Mycobacterium tuberculosis complex.   
Many studies have assessed the accuracy of PCR using IS6110 as the target 
sequence.  Most studies compared their results against Mtb culture results, which is 
the gold standard. Other studies, however, compared their PCR results against the 
clinical suspicion of tuberculosis (based on signs, symptoms and radiological 
findings).  Some authors compared PCR results to histopathological features that 
were suggestive of tuberculosis.  Sensitivities range from 72% to 100%, whilst 
specificities ranged from 73 to 99%,2,6,14,21,22,27,33,35,36 (Table 1).  However, it should 
be noted that many of these studies used samples that either had positive smear 
results or positive culture results for Mycobacterium tuberculosis, i.e. included 
samples with high bacterial loads.  
In a study conducted by Salian et al, 2 the authors compared the Mtb PCR results on 
formalin-fixed, paraffin embedded tissue to mycobacterium culture results in 53 of 
their 60 cases.  Their cases included tissue that was AFB positive on 
histopathological examination.  TB PCR (targeting IS6110) yielded a sensitivity of 
100% and a specificity of 93%.  Of their 3 false positive cases, 2 patients had a prior 
history of tuberculosis and in the third case, the patient had a good response to 
antituberculosis therapy despite the negative culture result.2 
Park and colleagues performed a study on formalin-fixed, paraffin embedded lung 
tissue.33 Of their 223 cases, 152 had mycobacterium culture results available. This 
study also included cases that were AFB positive.  Using the IS6110 gene target for 
PCR, and comparing the results with that of culture; TB PCR yielded a sensitivity of 
85% and a specificity of 99%.33 
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 Only one study was performed on cases of suspected tuberculosis, where 
histopathological examination revealed granulomatous inflammation but the Ziehl-
Neelsen stain failed to demonstrate acid-fast bacilli.14   In this study, the PCR result 
was compared against the clinical diagnosis and the results showed the lowest 
sensitivity and specificity as compared to other studies.  Only a proportion of cases 
(68 patients in whom there was a clinical suspicion of TB) had culture results 
available.  The authors subsequently compared the PCR results with the culture 
results and demonstrated a false positive rate of 34% and a false negative rate of 
4%.14  This study showed that in paucibacillary samples, PCR tends to demonstrate 
inferior results. 
Jain et al22  investigated the value of TB PCR in paucibacillary cases of suspected 
osteoarticular tuberculosis.  In this study, TB PCR was compared against the 
clinicoradiological diagnosis of TB and the 16sr RNA gene was the target for PCR. 
Notably, the mycobacterium culture result was positive in only 6 cases of clinically 
suspected TB, whilst the PCR was positive in 49 of the 50 cases.  The results of this 
study suggest that in paucibacillary cases, PCR may perform superiorly compared to 
culture.22 
Numerous other studies have evaluated the performance of TB PCR in 
microbiological specimens (such as sputum, pleural fluid, cerebrospinal fluid     
etc.).6, 36, 37  Majority of the studies utilised the IS6110 PCR target. Cheng et al 36 
included AFB positive specimens; reported a sensitivity of 75.9%, whilst Gholoobi et 
al6 reported a sensitivity of 58.3%.   
The 65KDa heat shock protein (hsp 65) is another commonly used target using 
nested PCR, followed in some instances by restriction fragment length polymerase 
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(RFLP) analysis.10  The hsp 65 gene is highly conserved in all mycobacterium 
species.  Its protein product contains genus specific epitopes.10  Hence, restriction 
enzyme digestion of the hsp 65 PCR product can be used in differentiating M. 
tuberculosis from other species. In a study conducted by Cook et al, 38 the authors 
developed a simple nested PCR protocol, in which amplification of a 133bp fragment 
of the hsp 65 gene, together with RFLP analysis using three restriction enzymes, 
was successfully able to detect and distinguish between M. tuberculosis and atypical 
species of mycobacteria.38  A study evaluating PCR using the hsp65 target showed a 
false positive rate of 27% (3 of 11 cases).  However, it was noted that in all three of 
these false positive cases, there was a culture confirmed diagnosis of M. avium 
complex.7  Other parameters that may affect the results of PCR include the type of 
fixatives used, the length of the PCR target and the concentration of the target DNA 
amplified.7  
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AUTHOR AND 
DATE 
N0. OF 
SPECIMENS 
TISSUE TYPE PCR 
TARGET 
FINDINGS 
 
Jackson et al, 
2000
14
 
 
 
115 specimens, 68 
were compared with 
culture results. 
 
 
FF-PE tissue. 
Pulmonary & 
extrapulmonary 
 
IS6110 
                                                          
Overall sensitivity: 72% 
Overall specificity: 72% 
Compared against culture:  
2FN and 22 FP 
 
 
Jain et al, 2008
22
 
 
 
50 cases from osteo-
articular sites 
 
PCR on fresh  tissue/ 
aspirate material 
 
16rs RNA 
                            
Comparing PCR with 
clinicoradiological 
diagnosis as gold standard: 
sensitivity: 78.6%    
specificity: 87.1%   
 
Salian et al, 1998
2
 
 
                     
60 cases, culture 
results available in 53 
cases. 
 
FF-PE tissue. 
Pulmonary & 
extrapulmonary 
 
IS6110 
                     
Sensitivity: 100%    
Specificity: 93%   
 
 
 
Park et al, 2003
27
 
 
 
 
 
81 cases, no culture 
results available 
 
FF-PE tissue. 
Pulmonary & 
extrapulmonary 
 
IS6110 
                                    
Comparing PCR with 
clinical diagnosis:        
Sensitivity: 78%     
Specificity: 88%   
 
Park et al, 2010
33
 
 
                     
223 cases, culture 
results available in 
152 cases. 
 
FF-PE lung tissue.  
 
IS6110 
                                     
Comparing PCR with 
culture:                   
Sensitivity: 85%     
Specificity: 99%                                    
 
Chawla et al, 2009
35
 
 
                     
104 cases, no culture 
results available 
 
PCR on fresh 
extrapulmonary 
tissue 
 
IS6110 
                                 
Comparing PCR with 
histopathology as gold 
standard:                  
sensitivity: 74.1%    
specificity: 96.1%   
 
Cheng et al, 2004
36
 
 
                     
155 cases, culture 
results available in 
112 cases 
        
Microbiological 
specimens (Fluids 
etc.) 
 
IS6110 
                             
Comparing PCR with 
culture:                   
Sensitivity: 75.9%      
 
Gholoobi et al, 
2012
6
 
 
 
30 cases 
 
 
Microbiological 
specimens (Fluids 
etc.) 
 
IS6110 
 
Comparing PCR with 
culture:                   
Sensitivity: 58.3%   
Specificity: 77.8%                                      
 
Thangappah et al, 
2011
21
 
 
72 cases, 49 cases 
submitted for PCR 
 
 
FF-PE tissue from 
female genital tract 
 
 
IS6110 & 
TRC4 
                             
Comparing PCR to clinical 
suspicion of TB:                   
Sensitivity: 57.1%      
 
Table 1: Comparison of the findings from similar studies investigating the efficacy of 
the mycobacterium PCR assay. FF-PE = Formalin fixed, paraffin embedded; FN = False 
negative; FP = False positive. 
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In a study conducted by Barcelos et al, 39 the authors illustrated that whilst the length 
of time that a specimen is fixed in formalin does not influence the PCR result; the 
type of formalin does. Specifically, buffered formalin presented better results as 
compared to 10% non-buffered formalin.39   Rish et al also showed that up to 7 days 
of fixation in 10% neutral buffered formalin had a negligible effect on the PCR test.34  
The longer the fragment length of an amplified target the greater the likelihood of 
degradation of the amplicon.  This is due to the fact that PCR products with a higher 
molecular weight tend to fragment more easily.  This was highlighted by Marchetti et 
al, 7 where the authors showed that PCR target sequences that were longer (223 and 
143 base pairs respectively), showed worse results in terms of sensitivity as 
compared to target sequences that were 106 and 123 base pairs in length.7   The 
same authors also showed that the concentration of DNA used may also influence 
the PCR result. In their study, DNA concentrations of 1microgram (µg) and 3µg 
yielded the best results in terms of sensitivity, whilst DNA concentrations of 5µg had 
the highest number of false negative results.7  
It is thus clear that several factors may influence the results of the PCR assay.  In 
order to optimize results, an individual laboratory should pay attention to all of the 
above mentioned factors when designing their PCR protocol. 
 
3.5 Limitations of the mycobacterium polymerase chain reaction assay 
3.5.1 False positive and false negative results 
Although TB PCR has been shown to be a rapid, sensitive and specific diagnostic 
test, it has some limitations. The major limitation of PCR is that it cannot distinguish 
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live from dead bacilli as the test is not dependent on bacterial replication.22, 35  As 
such, PCR results should be interpreted with caution in patients with reactivation TB, 
asymptomatic infection and in those who have recently received antituberculosis 
treatment.14, 35  In cases where the PCR test is positive but the subsequent culture 
result is negative, there is a major clinical dilemma as to whether antituberculosis 
treatment should be maintained or discontinued.  Many authors suggest that under 
these circumstances, if all precautions have been taken to avoid contamination of 
the PCR procedure, then the results of the positive PCR should be judged in light of 
the clinical picture and histopathological features. 14, 35, 36   
Due to the extremely sensitive nature of the PCR test, false positive results are 
mainly due to carry-over contamination. 14, 35, 21  Therefore, meticulous specimen 
handling, including DNA extraction and PCR setup should be undertaken for 
reliability of results.14 
False negative PCR results are mainly a consequence of the paucibacillary nature of 
extrapulmonary TB.  Other contributory factors for false negative PCR results include 
loss of DNA during extraction;  uneven distribution of mycobacteria in tissue 
samples; inadequate samples submitted for PCR;  extensive necrosis within the 
tissue and inhibitors to PCR that may be present in the sample. 14, 33, 35 In order to 
circumvent these problems, appropriate controls (internal control such as 
amplification of the beta-globin (β-globin) gene, as well as positive and negative 
controls) need to be incorporated to the PCR protocol.14 
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3.5.2 Advantages and disadvantages 
In summary, the advantages of PCR carried out on formalin-fixed, paraffin 
embedded tissue are as follows:  
1. It is a sensitive and rapid diagnostic assay, particularly useful if tissue has not 
been concurrently submitted for culture.22  
2. The test is of great value in circumstances where disease progression is rapid 
and destructive, and diagnosis by culture confirmation would delay treatment with 
undesirable and unfavourable consequences.22  
3. As PCR is a very sensitive test that can detect the presence of only a few bacilli, 
a very small quantity of specimen is required for a diagnosis to be made.26 
4.  PCR can differentiate between Mycobacterium tuberculosis complex and atypical 
mycobacterial species.22 
 The disadvantages of PCR carried out on formalin-fixed, paraffin embedded tissue 
are as follows:  
1. PCR cannot differentiate between dead and live bacterial organisms and as 
such, cannot differentiate between active, latent and recently treated disease.26 
2. The diagnostic accuracy of ‘in-house’ methods may be variable.12 
3. PCR has suboptimal sensitivity in paucibacillary cases. 14,33,35  
4. High initial capital costs and maintenance costs may limit is use in resource-poor 
settings.10 
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3.6 Conclusion: 
PCR is a rapid diagnostic test that may be very valuable especially in circumstances 
where tissue has not been concurrently submitted for TB culture.  However, due to 
the many factors that can alter the reliability and reproducibility of this molecular test, 
an individual laboratory should validate its use. 
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CHAPTER  4 
 
4. 0 Materials and Methods 
4.1 Clinical laboratory and hospital setting 
The department of Anatomical Pathology, University of Witwatersrand and the 
National Health Laboratory Services (NHLS) affords its services to patients within the 
greater Johannesburg region.  This includes patients attending Charlotte Maxeke 
Johannesburg Academic Hospital, Chris Hani Baragwanath Hospital, Helen Joseph 
Hospital and others. The histopathological reporting of all tissue samples from 
patients attending these hospitals is carried out by this department. 
The records of all cases of mycobacterium PCR that were performed on formalin-
fixed, paraffin embedded tissue samples in the department of Anatomical Pathology, 
University of Witwatersrand from the period 2008 to 2012 were retrieved. 
 
4.2 Study design 
This is a retrospective cross sectional, non-interventional laboratory based study. 
4.2.1 Sample  selection 
Using the ‘DISA’ laboratory database system, the histological reports for all cases 
showing granulomatous inflammation with subsequent negative Ziehl-Neelsen (ZN) 
stains for acid-fast bacilli were retrieved.  Using ‘DISA’, cases for which 
corresponding mycobacterium culture results were available, were then identified.  
The mycobacterium culture test must have been performed on a specimen retrieved 
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from the same site as the biopsy sample submitted for histology, or from a closely 
related site, e.g. bone marrow trephine submitted for histology and bone marrow 
aspirate submitted for mycobacterium culture evaluation.  
The histological haematoxylin and eosin (H&E) slides as well as the corresponding 
Ziehl-Neelsen (ZN) stains for each of these cases were reviewed by the author as 
well as a pathologist.  This was to ensure that the histological pattern of inflammation 
was indeed granulomatous and that the ZN stain was negative for acid-fast bacilli, 
(Figures 1- 4). 
The mycobacterium polymerase chain reaction results for all these selected cases 
were then reviewed. 
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Figure 1:  Necrotising granulomatous inflammation. This photomicrograph illustrates a 
necrotising granuloma comprising an aggregate of epithelioid histiocytes and Langhans-type 
giant cells; surrounded by a chronic inflammatory cell infiltrate. (H&E, 4 µm; original 
magnification 200x). 
 
Figure 2: Necrotising granulomatous inflammation with a giant cell at the centre of the 
field.   (H&E, 4 µm; original magnification 400x). 
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Figure 3: Positive Ziehl-Neelsen stain with acid-fast bacilli indicated by arrows.       
(ZN, 4 µm; original magnification 1000x). 
 
 
Figure 4: Necrotising granulomatous inflammation with a negative Ziehl-Neelsen 
stain.   (ZN, 4 µm; original magnification 400x). 
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4.2.2 Mycobacterium polymerase chain reaction  
A. DNA extraction/ isolation:  
Ten micrometre sections are prepared from the formalin fixed, paraffin embedded 
samples.  The blocks are sectioned using new blades for each sample to prevent 
cross contamination and the work area as well as work tools are cleaned with 3% 
Virkon between each block handled.  Work areas are also decontaminated with ultra 
violet light between subsequent procedures.  These processes are in place to control 
cross contamination. 
The paraffin is dissolved using 1ml xylene, followed by treatment with 1ml ethanol. 
Following centrifugation, DNA is extracted from the samples using the DNA Micro 
QIA amp kit (Qiagen, Whitehead Scientific), according to manufacturer’s instructions.  
DNA is quantified using the Nanodrop 1000 Spectrophotometer. 
 
B. Mycobacterium Nested PCR38 
Nested PCR is performed using primers designed to amplify a region of the gene 
encoding the 65-kDa mycobacterial heat shock protein.  
The first round of nested PCR produces amplicons that are of 310 and 231 base 
pairs in length.  The following components are added to obtain a 50 µl standard 
reaction:  “5µl of template DNA, 200µM dNTP’s (Roche), 0.38 µM of each primer viz. 
T1U1, T1U2 and T1D (Whitehead Scientific), (Table 2). 1.0U Taq DNA polymerase 
(Roche), 10x Reaction Buffer (with MgCl2, 15mM) in a total volume of 50µl”.  
The samples are placed in the 9700 Gene Amp PCR System (Life Technologies), 
under the following thermal conditions: “Initial denaturation to 94ºC for 4 minutes; 
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subsequent 35 cycles consistent of 94 ºC for 1 minute (denaturation), 57 ºC for 2 
minutes (annealing) and 72 ºC for 2 minutes (extension). A final extension at 72 ºC 
for 7 minutes completes the PCR run.” 
The second round of nested PCR results in a 133 bp product. For nested 
reamplification 5 µl of  first round PCR product is transferred into a 45 µl of master 
mix solution containing second primers T2U and T2D, (Table 2).  dNTP’s, primers 
and Taq DNA polymerase are maintained at the concentrations of the first round 
master mix.  PCR is repeated as above, except that an annealing temperature of 52 
ºC is used. 
 
C. Agarose gel electrophoresis: 
The amplified second round PCR products are then visualised by agarose gel 
electrophoresis. The PCR products are electrophoresed at 100 volts utilising a 3% 
agarose gel(Celtic Diagnostics). After completion of electrophoresis the amplified 
fragments are visualised with ethidium bromide (Merk) staining on a UV-
transilluminator and photographed. Positive samples appear as a visible band with a 
molecular size of 150bp, (Figure 5).  
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Figure 5: Agarose gel photograph of mycobacterium PCR products. A positive result is 
seen on lanes 5, 6 and 10. M= Molecular weight ladder at 50 bp gradations. 11= Positive 
control.        
 
D. Controls 
Both positive and negative controls are utilised.  The positive control includes 
paraffin embedded samples that had previously tested positive with the Ziehl-
Neelsen stain for acid-fast bacilli.  The negative control used includes a no-template 
control in which nuclease-free water is substituted as a template.  
Primers PC04/ GH20 (Whitehead Scientific), (Table 2), targeting the -globin 
housekeeping gene serves as a control for efficacy of extraction and amplification of 
DNA from paraffin embedded tissue material. 
 
E. Real-time amplification of the -globin gene40 
This assay is performed using the Corbett Research RotorGene 6000 (Whitehead 
Scientific) RT-PCR machine using the Bioline SensiMix™SYBR No-Rox kit (Celtic 
Diagnostics).  A final volume of 20 µl reaction mix is made using “0.2 mM of each 
 Page | 34  
 
primer, 10 µl 2x SensiMix™SYBR No-Rox Master Mix (with MgCl2, 50mM) and 2µl of 
template DNA”. The thermal cycling profile of this assay consists of an initial 
denaturation step at 95ºC  for 10 minutes, followed by 50 cycles consistent of  95ºC  
for 10 seconds (denaturation), 55ºC  for 10 seconds (annealing) and 72 ºC  for 15 
seconds (elongation).  After amplification, melt curve analysis is carried out at 95ºC 
with a ramp rate 1ºC/5seconds.  The average melting temperature (Tm) of the  
-globin amplicon is 85.5 ±1.0C. (see Annexure 1) 
 
 
Primer Name Sequence 
T1U1 5’-AAG GAG ATC GAG CTG GAG GA –3’ 
T1U2 5’-AGG CGT TGG TTC GCG AGG G –3’ 
T1D 5’-TGA TGA CGC CCT CGT TGC C –3’ 
T2U 5’-GTC TCA AAC GCG GCA TCG –3’ 
T2D 5’-GTC ACC GAT GGA CTG GTC –3’ 
PCO4 5'-CAA CTT CAT CCA CGT TCA CC-3' 
GH20 5'-GAA GAG CCA AGG ACA GGT AC-3' 
 
Table2: Mycobacterium PCR primers (T1U1, T1U2, T1D, T2U and T2D) and -globin 
PCR primers (PCO4 and GH20). 
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F. Interpretation of the PCR results: 
Given that the controls produce the expected results, the clinical samples are 
interpreted as follows: 
1. A sample in which a 133 bp fragment is amplified, is reported as positive, 
regardless of the outcome of the internal control. 
2. A sample in which a 133 bp fragment is not amplified, is reported as negative. 
3. A sample that is negative, in which the internal control is negative, is reported as 
invalid. 
 
4.3 Sample and sample size 
4.3.1 Inclusion criteria 
 Included in the study sample were histological cases from 2008 to 2012, 
where the histology showed granulomatous inflammation with a negative 
Ziehl-Neelsen stain.  
 All of these cases had to have been submitted for TB PCR and must have 
had a corresponding culture result. 
4.3.2 Exclusion criteria 
 Excluded from the study sample, were all cases wherein the histology slides 
or the original paraffin-embedded tissue blocks could not be retrieved from 
filing for review. 
 Cases that upon review were positive for acid-fast bacilli with the ZN stain, 
were excluded. 
 Excluded were cases where the culture result was reported as “contaminated 
specimen”.  
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4.3.3 Sample size calculation 
In a study carried out by the investigator in 2012, titled “A study to ascertain the 
number of cases with negative Ziehl-Neelsen granulomatous inflammation with a 
positive mycobacterium PCR result”, a total of 269 cases of mycobacterium PCR 
were performed in a period spanning one year. Extrapolating from this figure, in a 
five year period, the expected total number of mycobacterium PCR tests performed 
would be 1345. 
It is further estimated that only one third of the above cases would have a 
corresponding mycobacterium culture result, leaving 444 cases. An additional 10% 
of cases were excluded due to exclusion criteria.  
Therefore, for a population size of 400 with a confidence level of 95%; a precision 
level (margin of error) of 5% and a variability of 30%, the sample size is calculated at 
120. 
 
4.3.4 Final sample size 
After reviewing the histology slides and retrieval of the PCR results with the 
corresponding culture results, a sample size of 121 cases was attained. 
 
 
4.4 Collection and recording of data 
The information collected on each case was entered onto a data capture sheet (see 
Annexure 2).  This data was subsequently transferred into a Microsoft Office Excel 
(2007) spread sheet for data analysis. 
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4.5 Statistical  analysis 
4.5.1 Reproducibility and validity of results 
The reliability or reproducibility of a test is the ability of that test to produce 
comparable results each time that it is performed.41  The validity of a test is the 
likelihood that the results of a study are true and free of bias. This is dependent on 
the integrity of the study design.41 
The following steps were taken to ensure that this study would produce valid and 
reliable results: 
 An appropriate study design was chosen. 
 The test was conducted in a population where the prevalence of disease (i.e. 
tuberculosis) is high. 
 An appropriate sample size was met. 
 The test (i.e. TB PCR) was conducted using a standard, reproducible protocol 
with appropriate controls. 
 
4.5.2 Why specific tests have been used 
Descriptive statistics were used to describe the demographical information of the 
study population, i.e., age and gender distributions. 
As this study compares a diagnostic test against a gold standard test, the following 
statistical tests were performed: 
 Sensitivity – This is defined as the proportion of subjects with a particular 
disease who will have a positive result.42,43 
Sensitivity =
True positives
True positives + False negatives
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 Specificity – This is defined as the proportion of subjects without a particular 
disease who will have a negative result.42,43 
 Specificity =
True negatives
False positives+True negatives
 
 A major limitation of both sensitivity and specificity is that they are of no value 
in estimating the probability of disease in an individual patient.  It is of more 
practical use, when faced with an individual patient, to know the probability 
that a test result will give the correct diagnosis.  For this reason, positive and 
negative predictive values were also calculated. 42,43 
 
 Positive predictive value – is defined as the proportion of people with a 
positive test result who will truly have the disease. 42,43 
Positive predictive value =
True positives
True  positives + False positives
 
 Negative predictive value – is defined as the proportion of people with a 
negative test result who do not have the disease 42,43 
Negative predictive value =
True negatives
False negatives + True negatives
 
Both positive and negative predictive values are dependent on the prevalence of 
disease. 
Lastly, the Chi-square test was utilised in this study to determine the association 
between a positive TB PCR result and a TB culture result.  This test measures the 
probability of association between two discrete non-parametric variables.  A ‘p value’ 
of <0.05 was selected for this test.  A limitation of this test is that although it gives an 
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association between two variables, it does not measure the strength of the 
association.44 
4.6 Ethical considerations 
This was a retrospective study carried out on archived slides and paraffin wax 
embedded blocks.  The patients’ names were not recorded on the data capture 
sheet.  Each case was identified with consecutive numbers and laboratory numbers 
only.  The identity of the patient is known only to the principle investigator and was 
not divulged to anyone else.  The Department of Anatomical Pathology has been 
granted blanket approval by the committee for Research on Human Subjects 
(medical) of the University of the Witwatersrand to conduct such retrospective 
studies.  
However, a separate application was submitted to the Human Research Ethics 
Committee, University of the Witwatersrand, which has been approved, (clearance 
number: M140274), (see Annexure 4). 
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CHAPTER 5 
 
5.0 Results 
5.1 Patient demographics 
A total of 121 cases of Ziehl-Neelsen negative granulomatous inflammation with TB 
PCR and TB culture results were identified. 
Fifty two percent of the cohort (63/121) were male and 48% (58/121) were female 
(Figure 6). 
 
 
Figure 6: Percentage of males and females in the study sample. 
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The mean age of the study population was 35.3 years; with majority of patients 
(58.7%) falling within the 21-30 and 31-40 age categories (Figure 7). 
 
 
Figure 7: Age distribution of the study sample.  
 
Majority of cases were biopsies from extrapulmonary sites, whilst only 5% of 
samples were pulmonary biopsies.  A large proportion of cases (46%) were bone 
marrow trephine biopsies, with corresponding culture results obtained from the bone 
marrow aspirate.  Other biopsy sites included those from the vertebra, soft tissue, 
skin, lymph nodes, liver, neck region, synovium and bone (Figure 8). 
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Figure 8: Distribution of the biopsy sites.  Majority of samples (46%) were derived from 
the bone marrow, followed by the vertebra. 
 
 
5.2 Mycobacterium polymerase chain reaction results 
Of the 121 cases submitted for TB PCR, 51/121(42%) were positive whilst 
70/121(58%) were negative.  The cases that were submitted for TB culture showed a 
positive result in 39/121(32%) and a negative result in 82/121(68%) of cases (Figure 
9). 
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Figure 9: Graph depicting the overall mycobacterium PCR and culture results.  A 
higher percentage of cases were positive for PCR as compared to culture. 
 
Twenty five cases (20.7%) had positive TB PCR and positive TB culture results; 
whilst 46.3% (56/121) had negative TB PCR and TB culture results.  There were 14 
(11.6%) false negative cases and 26 (21.5%) false positive cases (Table 3). 
The sensitivity of nested mycobacterium PCR targeting hsp65 is 64.1%, whilst the 
specificity is 68.2%.  The positive and negative predictive values are 49% and 80% 
respectively.  The Chi-square statistic comparing the results of TB PCR results and 
TB culture results is 11.4 (p value = 0.000744).  These results are statistically 
significant, and highlight an association between PCR and culture.  
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CULTURE POSITIVE CULTURE NEGATIVE 
 
PCR POSITIVE 25 (20.7%) 26(21.5%) 
 
PCR NEGATIVE 14(11.6%) 56(46.3%) 
 
Table 3: Mycobacterium PCR compared to culture results. Twenty six cases had false 
positive results whilst 14 cases had false negative results. 
 
 
5.3 Results in patients in whom there was no clinical suspicion of tuberculosis 
Of the 121 patients, there was a clinical suspicion of tuberculosis in 73 (60.3%) of 
cases.   In 11 patients, there was no clinical suspicion and in 37 (30.6%) of cases, 
this information was not available.  
Mycobacterium PCR was however performed in these 11 cases as the histology 
showed granulomatous inflammation and considering the high prevalence of this 
disease in South Africa, it is not a disease to be missed. 
Of the 11 patients in whom there was no clinical suspicion of TB, 7 patients had 
negative TB PCR and culture results and 2 patients were positive by both PCR and 
culture.  There were 2 false positive and no false negative results (Figure 10). 
Amongst these 11 cases where tuberculosis was not suspected, 4 patients had 
malignant diagnoses.  In 2 of the 11 cases, the clinical suspicion was that of 
sarcoidosis (which also produces a histological pattern of granulomatous 
inflammation).  Both these cases had a negative TB PCR and culture result.  One 
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patient had a diagnosis of rheumatoid arthritis, and both the TB PCR and culture 
results were positive.  One patient had a clinical diagnosis of gout.  This patient had 
a positive TB PCR result with a negative culture result. In the remaining 3 cases, 
further clinical information was not available. 
 
 
Figure 10: Diagram illustrating the PCR assay results in patients in whom 
tuberculosis was not clinically suspected. TN= True negative; TP= True positive;       
FP= False positive; FN= False negative; n= number. 
 
5.4 Results in patients who were on empirical treatment for tuberculosis.  
Twelve of the 121 patients (9.9%) were on empirical TB treatment, for variable 
durations, at the time of biopsy.  The information regarding the treatment status for 
the remaining patients is unknown.  Of these 12 patients, 7 tested negative for both 
TB PCR and culture. Five of the 12 patients had a positive PCR test but were culture 
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negative.  None of the patients who were on empirical TB treatment tested PCR 
negative but culture positive. 
5.5 PCR results in comparison to culture results, including cases that were 
culture positive for mycobacterium other than tuberculosis (MOTT). 
There were 25 true positive cases.  Of these, 23/25 (92%), grew Mycobacterium 
tuberculosis by culture.  One case that was positive for mycobacterium PCR, grew 
Mycobacterium mucogenicum on culture.  This is a rapidly growing non tuberculous 
mycobacterium that is a well recognised cause of skin and soft tissue infections.  
This biopsy was indeed taken from a skin lesion from a patient’s nose.  One 
additional case that was positive for mycobacterium PCR and culture, unfortunately 
had insufficient material for species identification. 
There were 14 false negative PCR results.  Eleven of the 14 cases negative for 
PCR, grew M. tuberculosis complex by culture.  In 1 case, the culture result was 
positive for M. avium/ intracellulare and in another the culture was positive for 
Mycobacterium gordonae.  In the remaining cases there was insufficient material for 
species identification. 
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CHAPTER 6 
6.0 Discussion 
6.1 Summary of the main findings 
A retrospective study including 121 cases showing Ziehl-Neelsen negative, 
granulomatous inflammation, with corresponding mycobacterium culture and PCR 
results were included.   
The sites of tissue biopsy were predominantly extrapulmonary, with only 5% of 
biopsies originating from the lung.  The majority of the cases were derived from the 
marrow (46%), followed by the vertebrae (10%).  This highlights the observation that 
the majority of the cases that are submitted for histological evaluation are cases that 
are not amenable to FNAB.   
Of the 121 cases, nested mycobacterium PCR (targeting the 65kDa hsp65 gene) 
was positive in 51 cases (42%), whilst mycobacterium culture was positive in 39 
cases (32%). Using the culture result (from the same or related site as the tissue 
submitted for histology) as the gold standard for comparison, PCR yielded a 
sensitivity of 64.1% and a specificity of 68.2%. Positive and negative predictive 
values of 49% and 80% respectively were attained. The Chi square test showed 
good agreement (p < 0.05) between PCR and culture results. 
There was no significant difference in the number of males affected (52%), 
compared to females (48%).  However, the age distribution of the study sample 
revealed that majority of the patients (58.7%) fell into the 21-30 and 31-40 year 
categories.  This finding is concordant with the observation that  in high prevalence 
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countries such as South Africa, most cases of tuberculosis occur in patients in their 
twenties to forties; that is, the most economically productive generation.12 
Most of the biopsies were derived from extrapulmonary sites (95%).  A large 
proportion of the cases were bone marrow trephine biopsies, with the corresponding 
bone marrow aspirate samples that were submitted for mycobacterium culture.  The 
tissue evaluated for mycobacterium PCR was therefore not precisely the same 
tissue that was submitted for culture, which ultimately may have influenced the 
results.  However, this could not have been circumvented, as in practice; most 
clinicians fail to concurrently submit tissue in normal saline for culture evaluation. 
 
6.2 Comparison of results with those from other studies. 
In this study, nested PCR had sensitivity and specificity of 64.1% and 68.2% 
respectively. The test had a higher false positive rate (21.5%) as compared to the 
false negative rate (11,6%).  However, consideration needs to be given to the fact 
that this study was performed in a study sample where the Ziehl-Neelsen (ZN) stain 
was negative for acid-fast bacilli (AFB).   Hence, all samples were paucibacillary in 
nature.  Many of the prior studies performed on formalin-fixed, paraffin embedded 
tissue included samples that were positive for acid-fast bacilli.  Acknowledging the 
fact that in order for AFB to be identified with the ZN stain, 104 to 106 bacilli per 
millilitre of tissue or fluid is required, 13 thus by  including samples that are AFB 
positive, PCR is likely to achieve a higher sensitivity.  
A similar study to the current one was performed by Jackson et al. 14  The authors 
also investigated formalin-fixed, paraffin embedded tissue showing granulomatous 
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inflammation without demonstrable acid-fast bacilli.  The PCR target used in this 
study was IS6110. Although their initial sample size was 115 cases, a culture result 
was only available in 68 cases. When compared to the clinical diagnosis of 
tuberculosis, the sensitivity and specificity for Mtb PCR was 72% and 73% 
respectively.  When using the gold standard culture for comparison, this study 
demonstrated a false negative rate of 2.9% (2 of 68 cases) and a false positive rate 
of 32.3% (22 of 68 cases).14  Congruent  to the current study, (which demonstrated a 
false positive rate of 21.5%) Jackson et al also illustrated the finding of a higher false 
positive rate in paucibacillary tissue samples.14 
To the investigator’s knowledge, this is the only local study carried out on formalin-
fixed, paraffin embedded tissue without demonstrable AFB; using the hsp65 gene 
target for PCR. Although this study had inferior results with comparable studies; it 
must be noted that hsp65 is a pan-mycobacterial gene target; hence a higher false 
positive rate can be expected due to contaminants from other mycobacterial species.  
Cook et al38 have described false positive results when using the hsp65 gene target 
due to saprophytic “tap-water” species of mycobacteria that may have been 
introduced during tissue processing.38  In addition, a higher false negative rate can 
also be expected as only tissue without detectable acid-fast bacilli by the Ziehl-
Neelsen stain were included.  
 
 6.3 Clinical importance of specific findings. 
In the current study, there were 11 patients in whom the clinical differential diagnosis 
of mycobacterial infection was not considered.  However, as the histological pattern 
showed granulomatous inflammation, and granting consideration to the fact that 
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tuberculosis is so prevalent in South Africa; all the specimens were submitted for 
mycobacterium PCR.  In four of the eleven patients, a malignant diagnosis was 
queried (carcinoma in 2 cases, multiple myeloma in 1 case and Hodgkin lymphoma 
in 1 case).  In three of the cases, both the PCR and culture results were negative.  
One of these patients had a previous diagnosis of breast cancer and presented with 
a vertebral lesion that was subsequently biopsied. Although the clinical suspicion 
was that of metastatic breast carcinoma to the vertebra, both the mycobacterium 
PCR and the culture results were positive.  This highlights the value of PCR, as a 
delay in waiting for the culture result may have had undesirable and devastating 
consequences for the patient.  In two patients, the clinical diagnosis was that of 
sarcoidosis. Tuberculosis and sarcoidosis are clinical and histopathological 
mimickers of each other as they are both granulomatous diseases.45  However, the 
treatment of these two disease entities significantly differ and it thus crucial to make 
this distinction.  In the two patients in whom sarcoidosis was queried; both had 
negative mycobacterium PCR and culture results, thus verifying a diagnosis of 
sarcoidosis.  It is thus clear that in many different clinical scenarios, and when used 
in the correct clinical setting, mycobacterium PCR proves to be of significant value. 
Furthermore, within the present study, there were 12 patients who were on empirical 
antituberculosis treatment for an unspecified duration; prior to biopsy.  Five of these 
patients still had a positive PCR result despite a negative culture result.  Taking into 
consideration that these are  patients in whom the clinical suspicion was so high as 
to warrant empirical treatment, one has to question whether the PCR results are 
indeed  “false positive” results. PCR has a major limitation in that it cannot 
differentiate between dead and live bacilli.35,36  In addition, the mycobacterial load 
may remain substantially high despite treatment, even though the organisms are not 
 Page | 51  
 
capable of generating infection.37  It is also possible that even with the institution of 
treatment, as PCR is theoretically capable of detecting a single organism, the 
sample will have a positive result well into the course of treatment.  In a study by 
Yuen et al, 46 the authors showed that the TB PCR remained positive after four 
weeks of antituberculosis treatment in 29 patients, 16 of whom who had become 
culture negative.46  PCR is therefore not able to differentiate between active; and 
prior or recently treated disease.  Thus, a positive result under this circumstance has 
to be considered in the light of the clinical scenario, rather than assuming that it is 
false positive result.  It is also noteworthy that none of the patients in the current 
study who were on antituberculosis therapy, had a negative PCR result with a 
positive culture result.  A negative PCR result is thus useful in excluding tuberculosis 
as a diagnostic consideration.37  This finding is further substantiated by the higher 
negative predictive value (of 80%) that was achieved in this study. 
As the hsp 65 gene is highly conserved in all species of mycobacterium, the use of 
this gene target in the PCR assay cannot differentiate M. tuberculosis from other 
mycobacterium species.   The advantage of using this target is that PCR may aid in 
the diagnosis of atypical mycobacterial infections.  However, due to the nature of this 
being a pan-mycobacterial target, contamination from other mycobacterial species 
may result in a lower specificity of the test.  In the current study, one patient had a 
positive mycobacterium PCR result which grew M. mucogenicum on culture.  This 
case would have been negative and potentially missed if a M. tuberculosis species 
specific probe had been used. 
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6.4 Shortcomings or limitations of the study. 
A major limitation of this study is that it was retrospectively conducted; hence not all 
of the specimens submitted for histopathological examination and mycobacterium 
culture were derived from the exact same site. Although the biopsy sites were either 
the same or closely related, this may have produced a sampling error, which could 
have potentially affected either the PCR or culture results.  A second limitation is that 
the microbiological culture was not always performed on a tissue specimen.  For 
example, a pleural biopsy specimen may have been submitted for histopathology, 
whilst the pleural fluid may have been submitted for culture. Although the sites are 
closely related, the bacillary load present in each type of specimen may have 
differed, which may have impacted the results. 
A more accurate and reliable method would be conduction of a prospective study, 
wherein the investigator would receive a tissue sample in normal saline, and divided 
the same tissue for histopathological evaluation and culture. However, as many 
clinicians submit tissue immediately in formalin to maintain tissue preservation, this 
may be difficult to achieve in clinical practice. 
 
6.5 Directions for future research. 
As shown in this study, mycobacterium PCR is a useful tool for the diagnosis of Mtb. 
Although the sensitivity and specificity was lower compared to other similar studies, 
this was the only study that was conducted on paucibacillary tissue using the hsp65 
gene target. Additional research may be of value in determining the performance of a 
species specific probe, such as IS6110, on paucibacillary tissue. However, with 
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major technological advancements being made in the field of molecular pathology to 
improve our diagnostic abilities and hence our patients’ lives, it would be prudent to 
direct further research towards more recent technologies. For example, there would 
be great value in determining the use and efficacy of Xpert MTB/RIF technology in 
formalin fixed, paraffin embedded tissue samples. Additional research with larger 
sample sizes on the use of Xpert MTB/RIF on fresh or frozen tissue is also essential, 
in order to include this as part of the national policy guidelines.  If this were a feasible 
option, the diagnosis of extrapulmonary and smear negative pulmonary tuberculosis 
would be expedited.  
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CHAPTER 7 
 
7.0 Conclusion 
Despite the development of novel diagnostic assays; the diagnosis of tuberculosis, 
particularly extrapulmonary tuberculosis and smear negative pulmonary tuberculosis, 
remains challenging.  Major progress in the field of diagnostics has been made with 
the development of novel nucleic acid amplification techniques, which have a major 
advantage of delivering rapid results.   
The aim of this study was to investigate the validity of the mycobacterium PCR assay 
in formalin-fixed, paraffin embedded tissue showing granulomatous inflammation 
without demonstrable acid-fast bacilli.  Although the study revealed suboptimal 
sensitivity and specificity results, these figures cannot be interpreted at face value. 
The results of the mycobacterium polymerase chain reaction assay are of most value 
when used in conjunction with the patient’s clinical history, signs and symptoms, and 
other ancillary investigations. 
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ANNEXURES 
 
ANNEXURE 1:  Example of β-globin melt curve graph 
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ANNEXURE 2:  Data collection sheet 
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ANNEXURE 3:  Protocol approval certificate  
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ANNEXURE 4:  Ethics clearance certificate 
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ANNEXURE 5:  Turnitin Report 
 
 
 
